Document_And_Entity_Informatio
Document And Entity Information | 9 Months Ended |
Sep. 30, 2014 | |
Document And Entity Information [Abstract] | ' |
Document Type | '10-Q |
Amendment Flag | 'false |
Document Period End Date | 30-Sep-14 |
Document Fiscal Period Focus | 'Q3 |
Document Fiscal Year Focus | '2014 |
Entity Registrant Name | 'CHEMED CORP |
Trading Symbol | 'CHE |
Entity Central Index Key | '0000019584 |
Current Fiscal Year End Date | '--12-31 |
Entity Filer Category | 'Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 17,010,464 |
Consolidated_Balance_Sheet
Consolidated Balance Sheet (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Current assets | ' | ' |
Cash and cash equivalents | $18,562 | $84,418 |
Accounts receivable less allowances of $13,887 (2013 - $12,590) | 132,340 | 91,770 |
Inventories | 6,385 | 6,703 |
Current deferred income taxes | 14,543 | 20,257 |
Prepaid income taxes | 3,488 | 3,690 |
Prepaid expenses | 13,420 | 17,818 |
Total current assets | 188,738 | 224,656 |
Investments of deferred compensation plans | 47,780 | 42,465 |
Properties and equipment, at cost, less accumulated depreciation of $187,983 (2013 - $180,550) | 101,845 | 92,955 |
Identifiable intangible assets less accumulated amortization of $32,644 (2013 - $32,055) | 56,158 | 56,556 |
Goodwill | 466,844 | 466,871 |
Other assets | 8,143 | 10,198 |
Total Assets | 869,508 | 893,701 |
Current liabilities | ' | ' |
Accounts payable | 57,067 | 41,758 |
Current portion of long-term debt | 20,425 | 183,564 |
Income taxes | 4,608 | 111 |
Accrued insurance | 39,927 | 41,859 |
Accrued compensation | 50,412 | 48,323 |
Accrued legal | 685 | 23,210 |
Other current liabilities | 24,131 | 25,161 |
Total current liabilities | 197,255 | 363,986 |
Deferred income taxes | 27,853 | 27,301 |
Long-term debt | 153,125 | ' |
Deferred compensation liabilities | 47,736 | 42,348 |
Other liabilities | 11,108 | 11,176 |
Total Liabilities | 437,077 | 444,811 |
Commitments and contingencies | ' | ' |
STOCKHOLDERS' EQUITY | ' | ' |
Capital stock - authorized 80,000,000 shares $1 par; issued 33,199,078 shares (2013 - 32,245,226 shares) | 33,199 | 32,245 |
Paid-in capital | 528,973 | 481,011 |
Retained earnings | 745,077 | 686,114 |
Treasury stock - 16,287,526 shares (2013 - 14,660,427) | -877,067 | -752,634 |
Deferred compensation payable in Company stock | 2,249 | 2,154 |
Total Stockholders' Equity | 432,431 | 448,890 |
Total Liabilities and Stockholders' Equity | $869,508 | $893,701 |
Consolidated_Balance_Sheet_Par
Consolidated Balance Sheet (Parenthetical) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Thousands, except Share data, unless otherwise specified | ||
Consolidated Balance Sheet [Abstract] | ' | ' |
Accounts receivable, allowances | $13,887 | $12,590 |
Properties and equipment, accumulated depreciation | 187,983 | 180,550 |
Identifiable intangible assets, accumulated amortization | $32,644 | $32,055 |
Capital stock - authorized | 80,000,000 | 80,000,000 |
Capital stock - par value | $1 | $1 |
Capital stock - issued | 33,199,078 | 32,245,226 |
Treasury stock | 16,287,526 | 14,660,427 |
Consolidated_Statement_Of_Inco
Consolidated Statement Of Income (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Consolidated Statement Of Income [Abstract] | ' | ' | ' | ' |
Service revenues and sales | $358,389 | $340,886 | $1,076,871 | $1,064,725 |
Cost of services provided and goods sold (excluding depreciation) | 256,445 | 243,184 | 771,271 | 762,850 |
Selling, general and administrative expenses | 53,566 | 48,870 | 162,886 | 157,537 |
Depreciation | 7,450 | 6,971 | 21,871 | 20,665 |
Amortization | 717 | 1,190 | 2,461 | 3,498 |
Other operating expenses | ' | 11,461 | ' | 26,221 |
Total costs and expenses | 318,178 | 311,676 | 958,489 | 970,771 |
Income from operations | 40,211 | 29,210 | 118,382 | 93,954 |
Interest expense | -980 | -3,500 | -7,224 | -11,291 |
Other income - net | 705 | -90 | 2,277 | 3,312 |
Income before income taxes | 39,936 | 25,620 | 113,435 | 85,975 |
Income taxes | -15,351 | -8,188 | -43,913 | -31,657 |
Net income | $24,585 | $17,432 | $69,522 | $54,318 |
Earnings Per Share | ' | ' | ' | ' |
Net income | $1.44 | $0.96 | $4.03 | $2.95 |
Average number of shares outstanding | 17,039 | 18,184 | 17,263 | 18,436 |
Diluted Earnings Per Share | ' | ' | ' | ' |
Net income | $1.39 | $0.94 | $3.87 | $2.89 |
Average number of shares outstanding | 17,627 | 18,522 | 17,968 | 18,824 |
Cash Dividends Per Share | $0.22 | $0.20 | $0.62 | $0.56 |
Consolidated_Statement_Of_Cash
Consolidated Statement Of Cash Flows (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 |
Cash Flows from Operating Activities | ' | ' |
Net income | $69,522 | $54,318 |
Adjustments to reconcile net income to net cash provided by operating activities: | ' | ' |
Depreciation and amortization | 24,332 | 24,163 |
Deferred income taxes | 5,630 | -11,681 |
Provision for uncollectible accounts receivable | 9,573 | 8,211 |
Amortization of discount on convertible notes | 3,392 | 6,450 |
Stock option expense | 3,430 | 4,732 |
Amortization of debt issuance costs | 697 | 1,421 |
Noncash portion of long-term incentive compensation | 1,988 | 1,161 |
Changes in operating assets and liabilities, excluding amounts acquired in business combinations: | ' | ' |
Decrease/(increase) in accounts receivable | -50,027 | 5,293 |
Decrease in inventories | 318 | 329 |
Decrease/(increase) in prepaid expenses | 4,398 | -6,183 |
Increase/(decrease) in accounts payable and other current liabilities | -29,680 | 48,967 |
Increase in income taxes | 8,186 | 1,923 |
Increase in other assets | -3,138 | -5,002 |
Increase in other liabilities | 5,370 | 3,978 |
Excess tax benefit on share-based compensation | -3,737 | -2,507 |
Other sources | 755 | 285 |
Net cash provided by operating activities | 51,009 | 135,858 |
Cash Flows from Investing Activities | ' | ' |
Capital expenditures | -31,745 | -18,887 |
Business combinations, net of cash acquired | -250 | -2,210 |
Other sources | 189 | 139 |
Net cash used by investing activities | -31,806 | -20,958 |
Cash Flows from Financing Activities | ' | ' |
Proceeds from revolving line of credit | 308,600 | ' |
Payments on revolving line of credit | -233,800 | ' |
Payments on other long-term debt | -188,206 | ' |
Proceeds from other long-term debt | 100,000 | ' |
Purchases of treasury stock | -99,103 | -89,611 |
Dividends paid | -10,558 | -10,459 |
Capital stock surrendered to pay taxes on stock-based compensation | -6,121 | -4,280 |
Retirement of warrants | -2,645 | ' |
Proceeds from exercise of stock options | 22,123 | 13,125 |
Excess tax benefit on share-based compensation | 3,737 | 2,507 |
Increase/(decrease) in cash overdrafts payable | 22,233 | -10,928 |
Debt issuance costs | -939 | -1,108 |
Other uses | -380 | -473 |
Net cash used by financing activities | -85,059 | -101,227 |
Increase/(Decrease) in Cash and Cash Equivalents | -65,856 | 13,673 |
Cash and cash equivalents at beginning of year | 84,418 | 69,531 |
Cash and cash equivalents at end of period | $18,562 | $83,204 |
Basis_Of_Presentation
Basis Of Presentation | 9 Months Ended |
Sep. 30, 2014 | |
Basis Of Presentation [Abstract] | ' |
Basis Of Presentation | ' |
1. Basis of Presentation | |
As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries. | |
We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X. Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2013 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP. However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows. These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. | |
Revenue_Recognition
Revenue Recognition | 9 Months Ended | ||||||||||
Sep. 30, 2014 | |||||||||||
Revenue Recognition [Abstract] | ' | ||||||||||
Revenue Recognition | ' | ||||||||||
2. Revenue Recognition | |||||||||||
Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. VITAS recognizes revenue at the estimated realizable amount due from third-party payers. Medicare payments are subject to certain limitations, as described below. | |||||||||||
We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”). Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue. | |||||||||||
During the third quarter of 2014, we recorded $2.5 million Medicare cap liability for two programs’ projected 2014 measurement period liability. | |||||||||||
During the nine months ended September 30, 2014 we recorded a net Medicare cap liability of $1.8 million for two programs’ projected 2014 measurement period liability offset by the reversal of Medicare cap liability for amounts recorded in the fourth quarter of 2013 for projected 2014 measurement period liability. Also during the nine months ended September 30, 2014, we received notice from a third party intermediary for amounts accrued related to the 2013 measurement period. As a result we repaid $3.4 million. | |||||||||||
Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands): | |||||||||||
September 30, | |||||||||||
2014 | 2013 | ||||||||||
Beginning balance January 1, | $ | 8,260 | $ | 1,261 | |||||||
2014 measurement period | 1,796 | - | |||||||||
2013 measurement period | - | 3,161 | |||||||||
Payments | -3,439 | - | |||||||||
Ending balance September 30, | $ | 6,617 | $ | 4,422 | |||||||
Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment. There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care. The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care. The cost of charity care is as follows (in thousands): | |||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||
$ | 1,827 | $ | 1,909 | $ | 5,518 | $ | 5,793 | ||||
Segments
Segments | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Segments [Abstract] | ' | |||||||||||
Segments | ' | |||||||||||
3. Segments | ||||||||||||
Service revenues and sales and after-tax earnings by business segment are as follows (in thousands): | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||
Service Revenues and Sales | ||||||||||||
VITAS | $ | 265,384 | $ | 254,001 | $ | 789,822 | $ | 788,896 | ||||
Roto-Rooter | 93,005 | 86,885 | 287,049 | 275,829 | ||||||||
Total | $ | 358,389 | $ | 340,886 | $ | 1,076,871 | $ | 1,064,725 | ||||
After-tax Earnings | ||||||||||||
VITAS | $ | 21,593 | $ | 14,608 | $ | 60,645 | $ | 55,237 | ||||
Roto-Rooter | 9,848 | 8,181 | 30,599 | 19,218 | ||||||||
Total | 31,441 | 22,789 | 91,244 | 74,455 | ||||||||
Corporate | -6,856 | -5,357 | -21,722 | -20,137 | ||||||||
Net income | $ | 24,585 | $ | 17,432 | $ | 69,522 | $ | 54,318 | ||||
We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. | ||||||||||||
Earnings_Per_Share
Earnings Per Share | 9 Months Ended | |||||||||
Sep. 30, 2014 | ||||||||||
Earnings Per Share [Abstract] | ' | |||||||||
Earnings Per Share | ' | |||||||||
4. Earnings per Share | ||||||||||
Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding. Earnings and diluted earnings per share are computed as follows (in thousands, except per share data): | ||||||||||
Net Income | ||||||||||
For the Three Months Ended September 30, | Income | Shares | Earnings per Share | |||||||
2014 | ||||||||||
Earnings | $ | 24,585 | 17,039 | $ | 1.44 | |||||
Dilutive stock options | - | 416 | ||||||||
Nonvested stock awards | - | 151 | ||||||||
Impact of warrants outstanding | - | 21 | ||||||||
Diluted earnings | $ | 24,585 | 17,627 | $ | 1.39 | |||||
2013 | ||||||||||
Earnings | $ | 17,432 | 18,184 | $ | 0.96 | |||||
Dilutive stock options | - | 235 | ||||||||
Nonvested stock awards | - | 103 | ||||||||
Diluted earnings | $ | 17,432 | 18,522 | $ | 0.94 | |||||
Net Income | ||||||||||
For the Nine Months Ended September 30, | Income | Shares | Earnings per Share | |||||||
2014 | ||||||||||
Earnings | $ | 69,522 | 17,263 | $ | 4.03 | |||||
Dilutive stock options | - | 402 | ||||||||
Nonvested stock awards | - | 147 | ||||||||
Conversion of Notes and impact of warrants outstanding | - | 156 | ||||||||
Diluted earnings | $ | 69,522 | 17,968 | $ | 3.87 | |||||
2013 | ||||||||||
Earnings | $ | 54,318 | 18,436 | $ | 2.95 | |||||
Dilutive stock options | - | 287 | ||||||||
Nonvested stock awards | - | 101 | ||||||||
Diluted earnings | $ | 54,318 | 18,824 | $ | 2.89 | |||||
For the three and nine-month periods ended September 30, 2014, no stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive. For the three and nine-month periods ended September 30, 2013, 434,000 and 31,000 stock options, respectively, were excluded from the computation of diluted earnings per share. | ||||||||||
Diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875% Senior Convertible Notes (the “Notes”) on May 15, 2014. The dilutive impact of this conversion feature for the first nine months of 2014 was 135,000 shares. | ||||||||||
At the time we issued the Notes, as discussed in Note 5 below, we also sold warrants for the right to purchase approximately 2,477,000 Chemed shares in the future. During the quarter ended June 30, 2014, we settled these warrants with one counterparty representing half of the total warrants issued for $2.6 million. The amount paid was recorded as an adjustment to paid-in capital. The remaining half of the sold warrants remain outstanding and mature ratably from August 15 through December 8, 2014. The dilutive impact of the warrants was 21,000 shares for the three and nine months periods ended September 30, 2014. | ||||||||||
LongTerm_Debt
Long-Term Debt | 9 Months Ended | ||
Sep. 30, 2014 | |||
Long-Term Debt [Abstract] | ' | ||
Long-Term Debt | ' | ||
5. Long-Term Debt | |||
On May 15, 2014, we retired our Senior Convertible Notes (the “Notes”) outstanding. We paid the $187.0 million of principal outstanding using a combination of cash on-hand and our existing revolving credit facility. In addition, we issued 249,000 Chemed shares in conjunction with the conversion feature of the Notes. At the time we issued the Notes, we also entered into a purchased call transaction to offset any potential economic dilution resulting from the conversion feature in the Notes. As a result, we received 266,000 Chemed shares from the exercise of the purchased call transaction. The issuance of shares under the conversion feature of the Notes, as well as the receipt of shares from the purchased call transaction were recorded as adjustments to paid-in capital during the quarter ended June 30, 2014. | |||
On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”). Terms of the 2014 Credit Agreement consist of a five-year, $350 million revolving credit facility and a $100 million term loan. The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 113 basis points. | |||
The debt outstanding consists of the following: | |||
Revolver | $ | 74,800,000 | |
Term loan | 98,750,000 | ||
Total | 173,550,000 | ||
Current portion of term and revolving loan | -20,425,000 | ||
Long-term debt | $ | 153,125,000 | |
Scheduled principal payments of the term loan are as follows: | |||
2014 | $ | 1,250,000 | |
2015 | 6,250,000 | ||
2016 | 7,500,000 | ||
2017 | 8,750,000 | ||
2018 | 10,000,000 | ||
2019 | 65,000,000 | ||
$ | 98,750,000 | ||
Debt issuance costs associated with the existing credit agreement were not written-off as the lenders and their relative percentage participation in the facility did not change. With respect to the 2014 Credit Agreement, deferred financing costs were $0.9 million. The 2014 Credit Agreement contains the following quarterly financial covenants: | |||
Description | Requirement | ||
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) | < 3.50 to 1.00 | ||
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges) | > 1.50 to 1.00 | ||
Annual Operating Lease Commitment | < $50.0 million | ||
We are in compliance with all debt covenants as of September 30, 2014. We have issued $36.9 million in standby letters of credit as of September 30, 2014 for insurance purposes. Issued letters of credit reduce our available credit under the 2014 Credit Agreement. As of September 30, 2014, we have approximately $238.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. | |||
Other_Income_Net
Other Income - Net | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Other Income - Net [Abstract] | ' | |||||||||||
Other Income - Net | ' | |||||||||||
6. Other Income – Net | ||||||||||||
Other income -- net comprises the following (in thousands): | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||
Market value gains/(losses) on assets held in | ||||||||||||
deferred compensation trust | $ | 896 | $ | -189 | $ | 2,708 | $ | 2,346 | ||||
Loss on disposal of property and equipment | -167 | -101 | -493 | -180 | ||||||||
Interest income - net | -13 | 192 | -5 | 1,165 | ||||||||
Other - net | -11 | 8 | 67 | -19 | ||||||||
Total other income - net | $ | 705 | $ | -90 | $ | 2,277 | $ | 3,312 | ||||
StockBased_Compensation_Plans
Stock-Based Compensation Plans | 9 Months Ended |
Sep. 30, 2014 | |
Stock-Based Compensation Plans [Abstract] | ' |
Stock-Based Compensation Plans | ' |
7. Stock-Based Compensation Plans | |
On February 21, 2014, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted 10,340 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2016, the date at which such awards may vest. The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1.2 million. | |
On February 21, 2014, the CIC also granted 14,061 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2016. At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award. We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1.2 million. | |
Independent_Contractor_Operati
Independent Contractor Operations | 9 Months Ended | ||||||||||||
Sep. 30, 2014 | |||||||||||||
Independent Contractor Operations [Abstract] | ' | ||||||||||||
Independent Contractor Operations | ' | ||||||||||||
8. Independent Contractor Operations | |||||||||||||
The Roto-Rooter segment sublicenses with 68 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada. We had notes receivable from our independent contractors as of September 30, 2014 totaling $1.4 million (December 31, 2013 - $1.5 million). In most cases these loans are fully or partially secured by equipment owned by the contractor. The interest rates on the loans range from 0% to 8% per annum and the remaining terms of the loans range from 2 months to 5 years at September 30, 2014. We recorded the following from our independent contractors (in thousands): | |||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||
Revenues | $ | 8,751 | $ | 8,054 | $ | 26,964 | $ | 24,418 | |||||
Pretax profits | 4,946 | 4,243 | 15,341 | 13,015 | |||||||||
Retirement_Plans
Retirement Plans | 9 Months Ended | ||||||||||
Sep. 30, 2014 | |||||||||||
Retirement Plans [Abstract] | ' | ||||||||||
Retirement Plans | ' | ||||||||||
9. Retirement Plans | |||||||||||
All of the Company’s plans that provide retirement and similar benefits are defined contribution plans. These expenses include the impact of market gains and losses on assets held in deferred compensation plans. Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands): | |||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||
$ | 3,635 | $ | 2,098 | $ | 10,856 | $ | 9,796 | ||||
Legal_And_Regulatory_Matters
Legal And Regulatory Matters | 9 Months Ended |
Sep. 30, 2014 | |
Legal And Regulatory Matters [Abstract] | ' |
Legal And Regulatory Matters | ' |
10. Legal and Regulatory Matters | |
The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable. | |
Regulatory Matters and Litigation | |
On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, David Williams, and Timothy O’Toole, In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio). As the Company has previously disclosed, on February 6, 2014, the Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with Defendants. That settlement received final court approval on July 15, 2014, resulting in the dismissal of the case. No appeal of that judgment has since been filed. Defendants agreed to enter into this settlement in order to eliminate the burden, expense and distraction of further litigation. | |
In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas, United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”). The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations. In June 2012, the complaint was unsealed. The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations. The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed. In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants. The complaint was served on the VITAS entities on April 12, 2013. | |
Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”). In April 2012, the complaint was unsealed. The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations. Plaintiff filed an amended complaint in November 2012. The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services. The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate. The complaint was served on the defendants on April 12, 2013. On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries. The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively. | |
On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”). Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed. The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course. This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest. On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action. The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS. The defendants filed a motion to dismiss on September 24, 2013. The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. | |
On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”). The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344. The government partially intervened in Gonzales. The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit. It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest. | |
On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood, Urick, and Gonzales complaints with the 2013 Action. As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes. The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators. The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014. The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action. | |
VITAS has also received document subpoenas in related state matters. In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States. The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients. In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees. In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation. | |
The net costs incurred related to U.S. v. Vitas and related regulatory matters were $450,000 and a $591,000 credit for the three months ended September 30, 2014 and 2013, respectively. For the nine months ended September 30, 2014 and 2013, the net costs were $1.6 million and $1.4 million respectively. | |
In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance. On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.). It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant. Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare. The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. | |
On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio). She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant. Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls. The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants. The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole. Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. | |
On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6). On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware. Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke. Defendants intend to renew their motion to dismiss the claims and allegations in KBC once it has been determined how these two cases are to proceed. On October 15, 2014, the plaintiff in KBC filed a motion seeking to consolidate KBC and North, to have plaintiff KBC appointed the sole lead plaintiff and its counsel, Motley Rice, sole lead counsel, and to designate KBC the sole operative complaint. Plaintiff North has indicated that she does not oppose consolidation of the two cases, but otherwise opposes KBC’s motion with regard to the appointment of lead plaintiff and lead counsel and designation of the operative complaint. On October 20, 2014, the Court stayed Defendants’ obligation to answer, move, or otherwise respond to the complaints in KBC and North pending further order of the Court. | |
The Company intends to defend vigorously against the allegations in each of the above lawsuits. Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company. | |
Concentration_Of_Risk
Concentration Of Risk | 9 Months Ended |
Sep. 30, 2014 | |
Concentration Of Risk [Abstract] | ' |
Concentration Of Risk | ' |
11. Concentration of Risk | |
VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR. The Agreements renew automatically for three-year terms. Either party may cancel the Agreements at the end of any term by giving 30 days prior written notice. VITAS made purchases from OCR of $8.8 million and $9.7 million for the three months ended September 30, 2014 and 2013, respectively. VITAS made purchases from OCR of $26.5 million and $29.3 million for the nine months ended September 30, 2014 and 2013, respectively. For the three and nine month periods ending September 30, 2014 and 2013, respectively, purchases from this vendor represent approximately 90% of all pharmacy services used by VITAS. | |
Cash_Overdrafts_And_Cash_Equiv
Cash Overdrafts And Cash Equivalents | 9 Months Ended |
Sep. 30, 2014 | |
Cash Overdrafts And Cash Equivalents [Abstract] | ' |
Cash Overdrafts And Cash Equivalents | ' |
12. Cash Overdrafts and Cash Equivalents | |
Included in accounts payable at September 30, 2014 is cash overdrafts payable of $23.0 million (December 31, 2013 - $806,000). | |
From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. We had $68,000 in cash equivalents as of September 30, 2014. There was $23.1 million in cash equivalents as of December 31, 2013. The weighted average rate of return for our cash equivalents was 0.09% at September 30, 2014 and 0.08% at December 31, 2013. | |
Financial_Instruments
Financial Instruments | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Financial Instruments [Abstract] | ' | |||||||||||
Financial Instruments | ' | |||||||||||
13. Financial Instruments | ||||||||||||
FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. | ||||||||||||
The following shows the carrying value, fair value and the hierarchy for our financial instruments as of | ||||||||||||
September 30, 2014 (in thousands): | ||||||||||||
Fair Value Measure | ||||||||||||
Carrying Value | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||
Mutual fund investments of deferred | ||||||||||||
compensation plans held in trust | $ | 47,780 | $ | 47,780 | $ | - | $ | - | ||||
Long-term debt | 173,550 | - | 173,550 | - | ||||||||
All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value. | ||||||||||||
The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2013 (in thousands): | ||||||||||||
Fair Value Measure | ||||||||||||
Carrying Value | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||
Mutual fund investments of deferred | ||||||||||||
compensation plans held in trust | $ | 42,465 | $ | 42,465 | $ | - | $ | - | ||||
Long-term debt | 183,564 | 193,032 | - | - | ||||||||
For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments. | ||||||||||||
Capital_Stock_Repurchase_Plan_
Capital Stock Repurchase Plan Transactions | 9 Months Ended | ||||||||||||
Sep. 30, 2014 | |||||||||||||
Capital Stock Repurchase Plan Transactions [Abstract] | ' | ||||||||||||
Capital Stock Repurchase Plan Transactions | ' | ||||||||||||
14. Capital Stock Repurchase Plan Transactions | |||||||||||||
We repurchased the following capital stock for the three and nine-months ended September 30, 2014 and 2013: | |||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||
Shares repurchased | 400,000 | 1,032,754 | 1,082,934 | 1,313,455 | |||||||||
Weighted average price per share | $ | 101.53 | $ | 68.91 | $ | 91.51 | $ | 68.23 | |||||
In February 2014, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $22.7 million of authorization remaining under this share repurchase plan. | |||||||||||||
Recent_Accounting_Statements
Recent Accounting Statements | 9 Months Ended |
Sep. 30, 2014 | |
Recent Accounting Statements [Abstract] | ' |
Recent Accounting Statements | ' |
15. Recent Accounting Statements | |
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue. The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements. The guidance is effective for fiscal years beginning after December 15, 2016. We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures. | |
In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”. ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations and cash flows. | |
Revenue_Recognition_Tables
Revenue Recognition (Tables) | 9 Months Ended | ||||||||||
Sep. 30, 2014 | |||||||||||
Revenue Recognition [Abstract] | ' | ||||||||||
Schedule Of Medicare Cap Liability Activity | ' | ||||||||||
September 30, | |||||||||||
2014 | 2013 | ||||||||||
Beginning balance January 1, | $ | 8,260 | $ | 1,261 | |||||||
2014 measurement period | 1,796 | - | |||||||||
2013 measurement period | - | 3,161 | |||||||||
Payments | -3,439 | - | |||||||||
Ending balance September 30, | $ | 6,617 | $ | 4,422 | |||||||
Schedule Of Cost Of Charity Care | ' | ||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||
$ | 1,827 | $ | 1,909 | $ | 5,518 | $ | 5,793 | ||||
Segments_Tables
Segments (Tables) | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Segments [Abstract] | ' | |||||||||||
Service Revenues And Sales And After-Tax Earnings By Business Segment | ' | |||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||
Service Revenues and Sales | ||||||||||||
VITAS | $ | 265,384 | $ | 254,001 | $ | 789,822 | $ | 788,896 | ||||
Roto-Rooter | 93,005 | 86,885 | 287,049 | 275,829 | ||||||||
Total | $ | 358,389 | $ | 340,886 | $ | 1,076,871 | $ | 1,064,725 | ||||
After-tax Earnings | ||||||||||||
VITAS | $ | 21,593 | $ | 14,608 | $ | 60,645 | $ | 55,237 | ||||
Roto-Rooter | 9,848 | 8,181 | 30,599 | 19,218 | ||||||||
Total | 31,441 | 22,789 | 91,244 | 74,455 | ||||||||
Corporate | -6,856 | -5,357 | -21,722 | -20,137 | ||||||||
Net income | $ | 24,585 | $ | 17,432 | $ | 69,522 | $ | 54,318 | ||||
Earnings_Per_Share_Tables
Earnings Per Share (Tables) | 9 Months Ended | |||||||||
Sep. 30, 2014 | ||||||||||
Earnings Per Share [Abstract] | ' | |||||||||
Schedule Of Computation Of Earnings Per Share | ' | |||||||||
Net Income | ||||||||||
For the Three Months Ended September 30, | Income | Shares | Earnings per Share | |||||||
2014 | ||||||||||
Earnings | $ | 24,585 | 17,039 | $ | 1.44 | |||||
Dilutive stock options | - | 416 | ||||||||
Nonvested stock awards | - | 151 | ||||||||
Impact of warrants outstanding | - | 21 | ||||||||
Diluted earnings | $ | 24,585 | 17,627 | $ | 1.39 | |||||
2013 | ||||||||||
Earnings | $ | 17,432 | 18,184 | $ | 0.96 | |||||
Dilutive stock options | - | 235 | ||||||||
Nonvested stock awards | - | 103 | ||||||||
Diluted earnings | $ | 17,432 | 18,522 | $ | 0.94 | |||||
Net Income | ||||||||||
For the Nine Months Ended September 30, | Income | Shares | Earnings per Share | |||||||
2014 | ||||||||||
Earnings | $ | 69,522 | 17,263 | $ | 4.03 | |||||
Dilutive stock options | - | 402 | ||||||||
Nonvested stock awards | - | 147 | ||||||||
Conversion of Notes and impact of warrants outstanding | - | 156 | ||||||||
Diluted earnings | $ | 69,522 | 17,968 | $ | 3.87 | |||||
2013 | ||||||||||
Earnings | $ | 54,318 | 18,436 | $ | 2.95 | |||||
Dilutive stock options | - | 287 | ||||||||
Nonvested stock awards | - | 101 | ||||||||
Diluted earnings | $ | 54,318 | 18,824 | $ | 2.89 | |||||
LongTerm_Debt_Tables
Long-Term Debt (Tables) | 9 Months Ended | ||
Sep. 30, 2014 | |||
Long-Term Debt [Abstract] | ' | ||
Debt Outstanding | ' | ||
Revolver | $ | 74,800,000 | |
Term loan | 98,750,000 | ||
Total | 173,550,000 | ||
Current portion of term and revolving loan | -20,425,000 | ||
Long-term debt | $ | 153,125,000 | |
Schedule of Principal Payments of the Term Loan | ' | ||
2014 | $ | 1,250,000 | |
2015 | 6,250,000 | ||
2016 | 7,500,000 | ||
2017 | 8,750,000 | ||
2018 | 10,000,000 | ||
2019 | 65,000,000 | ||
$ | 98,750,000 | ||
Financial Debt Covenants | ' | ||
Description | Requirement | ||
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) | < 3.50 to 1.00 | ||
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges) | > 1.50 to 1.00 | ||
Annual Operating Lease Commitment | < $50.0 million | ||
Other_Income_Net_Tables
Other Income - Net (Tables) | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Other Income - Net [Abstract] | ' | |||||||||||
Schedule Of Other Income - Net | ' | |||||||||||
Three months ended September 30, | Nine months ended September 30, | |||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||
Market value gains/(losses) on assets held in | ||||||||||||
deferred compensation trust | $ | 896 | $ | -189 | $ | 2,708 | $ | 2,346 | ||||
Loss on disposal of property and equipment | -167 | -101 | -493 | -180 | ||||||||
Interest income - net | -13 | 192 | -5 | 1,165 | ||||||||
Other - net | -11 | 8 | 67 | -19 | ||||||||
Total other income - net | $ | 705 | $ | -90 | $ | 2,277 | $ | 3,312 | ||||
Independent_Contractor_Operati1
Independent Contractor Operations (Tables) | 9 Months Ended | ||||||||||||
Sep. 30, 2014 | |||||||||||||
Independent Contractor Operations [Abstract] | ' | ||||||||||||
Schedule Of Independent Contractors | ' | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||
Revenues | $ | 8,751 | $ | 8,054 | $ | 26,964 | $ | 24,418 | |||||
Pretax profits | 4,946 | 4,243 | 15,341 | 13,015 | |||||||||
Retirement_Plans_Tables
Retirement Plans (Tables) | 9 Months Ended | ||||||||||
Sep. 30, 2014 | |||||||||||
Retirement Plans [Abstract] | ' | ||||||||||
Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans | ' | ||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||
$ | 3,635 | $ | 2,098 | $ | 10,856 | $ | 9,796 | ||||
Financial_Instruments_Tables
Financial Instruments (Tables) | 9 Months Ended | |||||||||||
Sep. 30, 2014 | ||||||||||||
Financial Instruments [Abstract] | ' | |||||||||||
Carrying Value, Fair Value And Hierarchy Of Financial Instruments | ' | |||||||||||
The following shows the carrying value, fair value and the hierarchy for our financial instruments as of | ||||||||||||
September 30, 2014 (in thousands): | ||||||||||||
Fair Value Measure | ||||||||||||
Carrying Value | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||
Mutual fund investments of deferred | ||||||||||||
compensation plans held in trust | $ | 47,780 | $ | 47,780 | $ | - | $ | - | ||||
Long-term debt | 173,550 | - | 173,550 | - | ||||||||
All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value. | ||||||||||||
The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2013 (in thousands): | ||||||||||||
Fair Value Measure | ||||||||||||
Carrying Value | Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | |||||||||
Mutual fund investments of deferred | ||||||||||||
compensation plans held in trust | $ | 42,465 | $ | 42,465 | $ | - | $ | - | ||||
Long-term debt | 183,564 | 193,032 | - | - | ||||||||
Capital_Stock_Repurchase_Plan_1
Capital Stock Repurchase Plan Transactions (Tables) | 9 Months Ended | ||||||||||||
Sep. 30, 2014 | |||||||||||||
Capital Stock Repurchase Plan Transactions [Abstract] | ' | ||||||||||||
Schedule Of Capital Stock Repurchases | ' | ||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||
Shares repurchased | 400,000 | 1,032,754 | 1,082,934 | 1,313,455 | |||||||||
Weighted average price per share | $ | 101.53 | $ | 68.91 | $ | 91.51 | $ | 68.23 | |||||
Revenue_Recognition_Narrative_
Revenue Recognition (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended |
Sep. 30, 2014 | Sep. 30, 2014 | |
Revenue Recognition [Abstract] | ' | ' |
Payments for medicare cap liability | ' | $3,439,000 |
Increase (decrease) in Medicare cap liability | $2,500,000 | $1,800,000 |
Revenue_Recognition_Schedule_O
Revenue Recognition (Schedule Of Medicare Cap Liability Activity) (Details) (USD $) | 9 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 |
Revenue Recognition [Abstract] | ' | ' |
Beginning Balance January 1, | $8,260 | $1,261 |
2014 measurement period | 1,796 | ' |
2013 measurement period | ' | 3,161 |
Payments | -3,439 | ' |
Ending Balance September 30, | $6,617 | $4,422 |
Revenue_Recognition_Schedule_O1
Revenue Recognition (Schedule Of Cost Of Charity Care) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Revenue Recognition [Abstract] | ' | ' | ' | ' |
Charity care cost | $1,827 | $1,909 | $5,518 | $5,793 |
Segments_Service_Revenues_And_
Segments (Service Revenues And Sales And After-Tax Earnings By Business Segment) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Total service revenues and sales | $358,389 | $340,886 | $1,076,871 | $1,064,725 |
Net income | 24,585 | 17,432 | 69,522 | 54,318 |
Operating Segments [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Total service revenues and sales | 358,389 | 340,886 | 1,076,871 | 1,064,725 |
Net income | 31,441 | 22,789 | 91,244 | 74,455 |
Corporate Segment [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Net income | -6,856 | -5,357 | -21,722 | -20,137 |
Segment VITAS [Member] | Operating Segments [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Total service revenues and sales | 265,384 | 254,001 | 789,822 | 788,896 |
Net income | 21,593 | 14,608 | 60,645 | 55,237 |
Segment Roto-Rooter [Member] | Operating Segments [Member] | ' | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' |
Total service revenues and sales | 93,005 | 86,885 | 287,049 | 275,829 |
Net income | $9,848 | $8,181 | $30,599 | $19,218 |
Earnings_Per_Share_Narrative_D
Earnings Per Share (Narrative) (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Millions, except Share data, unless otherwise specified | Sep. 30, 2014 | Jun. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Earnings Per Share [Abstract] | ' | ' | ' | ' | ' |
Stock options excluded from computation of earnings per share | 0 | ' | 434,000 | 0 | 31,000 |
Shares issued in conjunction with the conversion feature of the Notes | ' | ' | ' | 249,000 | ' |
Percent Of Senior Convertible Notes | 1.88% | ' | ' | 1.88% | ' |
Conversion of Notes and impact of warrants outstanding, Shares | 21,000 | ' | ' | 156,000 | ' |
Number of shares called by warrants | 2,477,000 | ' | ' | 2,477,000 | ' |
Warrants settled and recorded as an adjustment to paid in capital | ' | $2.60 | ' | ' | ' |
Earnings_Per_Share_Schedule_Of
Earnings Per Share (Schedule Of Computation Of Earnings Per Share) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Earnings Per Share [Abstract] | ' | ' | ' | ' |
Earnings, Income | $24,585 | $17,432 | $69,522 | $54,318 |
Diluted earnings, Income | $24,585 | $17,432 | $69,522 | $54,318 |
Earnings per Share | $1.44 | $0.96 | $4.03 | $2.95 |
Earnings per Share, Diluted | $1.39 | $0.94 | $3.87 | $2.89 |
Net Income, Earnings, Shares | 17,039,000 | 18,184,000 | 17,263,000 | 18,436,000 |
Dilutive stock options, Shares | 416,000 | 235,000 | 402,000 | 287,000 |
Nonvested stock awards, Shares | 151,000 | 103,000 | 147,000 | 101,000 |
Conversion of Notes and impact of warrants outstanding, Shares | 21,000 | ' | 156,000 | ' |
Net Income, Diluted Earnings, Shares | 17,627,000 | 18,522,000 | 17,968,000 | 18,824,000 |
LongTerm_Debt_Narrative_Detail
Long-Term Debt (Narrative) (Details) (USD $) | 9 Months Ended |
Sep. 30, 2014 | |
Debt Instrument [Line Items] | ' |
Repayment of convertible notes | $187,000,000 |
Shares issued in conjunction with the conversion feature of the Notes | 249,000 |
Stock received in written call transaction | 266,000 |
Standby letters of credit issued | 36,900,000 |
Unused lines of credit | 238,300,000 |
2014 Credit Agreement [Member] | ' |
Debt Instrument [Line Items] | ' |
Debt instrument term | '5 years |
Deferred financing costs | 900,000 |
2014 Credit Agreement [Member] | LIBOR [Member] | ' |
Debt Instrument [Line Items] | ' |
Basis spread on variable interest rate | 1.13% |
2014 Credit Agreement [Member] | Revolving Credit Facility [Member] | ' |
Debt Instrument [Line Items] | ' |
Face amount of debt | 350,000,000 |
2014 Credit Agreement [Member] | Medium-term Notes [Member] | ' |
Debt Instrument [Line Items] | ' |
Face amount of debt | $100,000,000 |
LongTerm_Debt_Debt_Outstanding
Long-Term Debt (Debt Outstanding) (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
Debt Instrument [Line Items] | ' | ' |
Total | $173,550,000 | ' |
Current portion of term loan and revolving loan | -20,425,000 | -183,564,000 |
Long-term debt | 153,125,000 | ' |
Revolving Credit Facility [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Total | 74,800,000 | ' |
Medium-term Notes [Member] | ' | ' |
Debt Instrument [Line Items] | ' | ' |
Total | $98,750,000 | ' |
LongTerm_Debt_Schedule_of_Prin
Long-Term Debt (Schedule of Principal Payments of the Term Loan) (Details) (USD $) | Sep. 30, 2014 |
Debt Instrument [Line Items] | ' |
Total | $173,550,000 |
Medium-term Notes [Member] | ' |
Debt Instrument [Line Items] | ' |
2014 | 1,250,000 |
2015 | 6,250,000 |
2016 | 7,500,000 |
2017 | 8,750,000 |
2018 | 10,000,000 |
2019 | 65,000,000 |
Total | $98,750,000 |
LongTerm_Debt_Financial_Debt_C
Long-Term Debt (Financial Debt Covenants) (Details) (USD $) | 9 Months Ended |
In Millions, unless otherwise specified | Sep. 30, 2014 |
Long-Term Debt [Abstract] | ' |
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA), Requirement | 3.5 |
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges), Requirement | 1.5 |
Annual Operating Lease Commitment, Requirement | $50 |
Other_Income_Net_Schedule_Of_O
Other Income - Net (Schedule Of Other Income - Net) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Other Income - Net [Abstract] | ' | ' | ' | ' |
Market value gains/(losses) on assets held in deferred compensation trust | $896 | ($189) | $2,708 | $2,346 |
Loss on disposal of property and equipment | -167 | -101 | -493 | -180 |
Interest income - net | -13 | 192 | -5 | 1,165 |
Other - net | -11 | 8 | 67 | -19 |
Total other income - net | $705 | ($90) | $2,277 | $3,312 |
StockBased_Compensation_Plans_
Stock-Based Compensation Plans (Narrative) (Details) (USD $) | 0 Months Ended | 9 Months Ended |
In Millions, except Share data, unless otherwise specified | Feb. 21, 2014 | Sep. 30, 2014 |
Performance Based TSR [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Stock awards granted | 10,340 | ' |
Shares vesting period, years | ' | '3 years |
Cumulative compensation expense | $1.20 | ' |
Performance Based EPS [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Stock awards granted | 14,061 | ' |
Shares vesting period, years | ' | '3 years |
Cumulative compensation expense | $1.20 | ' |
Independent_Contractor_Operati2
Independent Contractor Operations (Narrative) (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 | Sep. 30, 2014 | Sep. 30, 2014 | Sep. 30, 2014 |
In Millions, unless otherwise specified | Settlements of Roto-Rooter segment [Member] | Maximum [Member] | Minimum [Member] | ||
item | |||||
Independent Contractor Operations [Line Items] | ' | ' | ' | ' | ' |
Independent contractors with sublicenses | ' | ' | 68 | ' | ' |
Notes receivable from independent contractors | $1 | $1.50 | ' | ' | ' |
Interest rates on loans | ' | ' | ' | 8.00% | 0.00% |
Terms of the loans to independent contractors, years | ' | ' | ' | '5 years | '2 months |
Independent_Contractor_Operati3
Independent Contractor Operations (Schedule Of Independent Contractors) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Independent Contractor Operations [Abstract] | ' | ' | ' | ' |
Revenues | $8,751 | $8,054 | $26,964 | $24,418 |
Pretax profits | $4,946 | $4,243 | $15,341 | $13,015 |
Retirement_Plans_Schedule_Of_E
Retirement Plans (Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans) (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Retirement Plans [Abstract] | ' | ' | ' | ' |
Defined contribution plans | $3,635 | $2,098 | $10,856 | $9,796 |
Legal_And_Regulatory_Matters_D
Legal And Regulatory Matters (Details) (U.S. v. VITAS [Member], USD $) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
U.S. v. VITAS [Member] | ' | ' | ' | ' |
Loss Contingencies [Line Items] | ' | ' | ' | ' |
Number of Patients | ' | ' | 117 | ' |
Current and former employees | ' | ' | 10 | ' |
Net (costs) credit incurred | ($450,000) | $591,000 | ($1,600,000) | ($1,400,000) |
Concentration_Of_Risk_Details
Concentration Of Risk (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 |
Concentration Of Risk [Abstract] | ' | ' | ' | ' |
Period of renewal of pharmacy services agreements | ' | ' | '3 years | ' |
Number of days prior written notice to cancel agreements | ' | ' | '30 days | ' |
VITAS made purchases from OCR | $8.80 | $9.70 | $26.50 | $29.30 |
Percentage of concentration risk services represent from vendor | 90.00% | 90.00% | 90.00% | 90.00% |
Cash_Overdrafts_And_Cash_Equiv1
Cash Overdrafts And Cash Equivalents (Details) (USD $) | 9 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2014 | Dec. 31, 2013 |
Cash Overdrafts And Cash Equivalents [Abstract] | ' | ' |
Cash overdrafts included in accounts payable | ' | $806 |
Cash equivalents | $68 | $23,100 |
Cash equivalents weighted average rate of return | 0.09% | 0.08% |
Financial_Instruments_Carrying
Financial Instruments (Carrying Value, Fair Value And Hierarchy Of Financial Instruments) (Details) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
In Thousands, unless otherwise specified | ||
Carrying Value [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Mutual fund investments of deferred compensation plans held in trust | $47,780 | $42,465 |
Long-term debt | 173,550 | 183,564 |
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Mutual fund investments of deferred compensation plans held in trust | 47,780 | 42,465 |
Long-term debt | ' | 193,032 |
Significant Other Observable Inputs (Level 2) [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Long-term debt | $173,550 | ' |
Capital_Stock_Repurchase_Plan_2
Capital Stock Repurchase Plan Transactions (Details) (USD $) | 3 Months Ended | 9 Months Ended | |||
In Millions, except Share data, unless otherwise specified | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Feb. 28, 2013 |
Capital Stock Repurchase Plan Transactions [Abstract] | ' | ' | ' | ' | ' |
Stock repurchase program, amount authorized | ' | ' | ' | ' | $100 |
Shares repurchased | 400,000 | 1,032,754 | 1,082,934 | 1,313,455 | ' |
Weighted average price per share | $101.53 | $68.91 | $91.51 | $68.23 | ' |